OncoSec Medical (NSDQ:ONCS) expanded its relationship with Merck (NYSE:MRK) today, announcing a deal to combine its ImmunoPulse IL-12 device with Merck’s anti-PD-1 therapy, Keytruda, in a Phase II trial of patients with triple negative breast cancer.
The trial is slated to study the drug-device combination in patients with inoperable locally advanced or metastatic cancer who have failed at least one systemic chemotherapy or immunotherapy.
Get the full story at our sister site, Drug Delivery Business News.
The post OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial appeared first on MassDevice.
from MassDevice https://ift.tt/2I5ZBHc
Cap comentari:
Publica un comentari a l'entrada